Public Employees Retirement System of Ohio Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Public Employees Retirement System of Ohio trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 58,338 shares of the biopharmaceutical company’s stock after selling 433 shares during the period. Public Employees Retirement System of Ohio owned approximately 0.05% of Regeneron Pharmaceuticals worth $61,327,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in REGN. Sequoia Financial Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 5.0% in the second quarter. Sequoia Financial Advisors LLC now owns 1,522 shares of the biopharmaceutical company’s stock worth $1,600,000 after buying an additional 73 shares in the last quarter. Cooper Financial Group purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $293,000. Ameliora Wealth Management Ltd. grew its holdings in shares of Regeneron Pharmaceuticals by 2.9% during the 2nd quarter. Ameliora Wealth Management Ltd. now owns 3,354 shares of the biopharmaceutical company’s stock valued at $3,525,000 after purchasing an additional 96 shares during the last quarter. Diversified Trust Co raised its position in Regeneron Pharmaceuticals by 1.9% in the 2nd quarter. Diversified Trust Co now owns 1,209 shares of the biopharmaceutical company’s stock worth $1,271,000 after purchasing an additional 22 shares during the period. Finally, AA Financial Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 14.2% in the second quarter. AA Financial Advisors LLC now owns 345 shares of the biopharmaceutical company’s stock worth $363,000 after purchasing an additional 43 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $778.00 on Monday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $735.95 and a 12 month high of $1,211.20. The stock has a market cap of $85.49 billion, a price-to-earnings ratio of 19.25, a PEG ratio of 3.00 and a beta of 0.08. The company’s 50 day moving average is $876.85 and its two-hundred day moving average is $1,011.88.

Wall Street Analyst Weigh In

Several brokerages have weighed in on REGN. Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. Morgan Stanley lowered their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Finally, JPMorgan Chase & Co. reduced their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. One analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,107.29.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.